IL6 and cardiovascular disorder: Importantly, more comprehensive analyses in the MONICA/KORA trial revealed that the surfeit risk for cardiovascular disease events was mitigated by ≥10% after additional adjustment for serum levels of high-sensitivity C-reactive protein, IL-6, myeloperoxidase, soluble E-selectin, or soluble intercellular adhesion molecule-1.